GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of three years of biopsy threads, summarised so you do not have to read them — 68 comments in the full submission. View in context.
1.2k
c/survodutide·submitted 1 year ago by u/quant_not_qual

three years of biopsy threads, summarised so you do not have to read them

Discussionbranch of 11 comments

Been lurking in c/t2dglp1 for about 7 months and finally have something worth posting. Short version: week 68, 0.25mg, and hepatic fat is the bit I still cannot get a straight answer on. I have read the wiki, I have read the last 33 threads, and the answers split roughly down the middle. What I actually want to know…

Read the full submission and all 68 comments →

This branch

11 comments, started 1 year ago
u/andres_dahlberg24 points·1 year ago

Crossposting this to c/t2dglp1 because the people who need it are not reading this community.

replysharereportpermalink
u/preservative_free_p6 points·1 year ago

Which trial arm?

replysharereportpermalink
u/rania_salinas2 points·1 year ago

MASH claims need the trial and the biopsy endpoint

replysharereportpermalink
u/lyophile_lou5 points·1 year ago·edited

Which trial arm?

Yes, exactly this, and it is the bit that took me 6 weeks to accept.

replysharereportpermalink
u/cato_girard6 points·1 year ago

the MASH indication changes the risk calculus

replysharereportpermalink
u/incretin_ivypharmacology16 points·1 year ago

Which trial arm?

replysharereportpermalink
u/teodor_szabo6 points·1 year ago

glucagon co-agonism has a different safety story

replysharereportpermalink
u/diego_szabo-23 points·1 year ago

Hepatic fat or MASH or what?

replysharereportpermalink
u/injection_site_iris-28 points·1 year ago

the safety profile is not just tirzepatide amplified

replysharereportpermalink
u/zeynep_ndiaye3 points·1 year ago

The confident tone is doing a lot of work that the evidence is not.

replysharereportpermalink
u/tuva_kirchner1 point·1 year ago·edited

hepatic fat and survodutide are the story

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →